Atlas Trials

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

Clinical trial NCT05362942 · UNKNOWN

Trial details

NCT number
NCT05362942
Sponsor
Beijing 302 Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaMinimal Residual Disease
Start date
2022-05-01
Primary completion
2023-04-30
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.